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INTRODUCTION
Use of neuromuscular blocking (NMB) drugs in the intensive care unit (ICU)
increased dramatically in the 1980s but has decreased recently [1, 2]. Currently, it is esti-
mated that <5 percent of ICU patients receive continuous administration of NMB drugs
for 24 hours or more [2]. Utilization is tempered by recognition of untoward side-effects
and complications associated with prolonged administration ofNMB drugs [3], including
NMB drug toxicity, drug-drug interactions and prolonged weakness or myopathy [4],
most notably in patients with the syndromes ofsystemic inflammation (SIRS), acute renal
failure andmultiple organ dysfunction syndrome [5-12]. In addition, NMB drugs may pre-
cipitate hemodynamic, autonomic and other physiologic interactions in ICU patients.
NMB drugs are used in the ICU to facilitate mechanical ventilation, as adjunctive
therapy in the control of intracranial hypertension, to eliminate shivering and decrease
oxygen consumption, as supportive therapy of tetanus or status epilepticus (with EEG
monitoring), to optimize conditions for certain diagnostic procedures and to facilitate
endotracheal intubation [13]. Other less common (and controversial) indications are to
ensure patient immobility during invasive procedures or patient transport, emergent con-
trol of agitated or combative patient, and selected patients with severe cardiovascular
instability.
While all NMB drugs interact with the postjunctional nicotinic acetylcholine (nACh)
receptor [14], they exhibit unique pharmacologic and clinical profiles [13]. In addition,
NMB drugs vary significantly in acquisition costs [15]. The use of these drugs may con-
stitute a large proportion of the ICU pharmacy budget. However, pharmaco-economic
evaluation of ICU drug use must take into account secondary costs such as personnel
requirements, use ofinfusion devices, long-term effects ofdrug and drug metabolites and
potential patient morbidity or mortality secondary to side-effects of specific drugs [16].
THE NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE
NMB drugs reversibly block impulse transmission at the nicotinic acetylcholine
receptor (nAChR), clustered at the neuromuscular junction of skeletal muscle [17].
Historically, the nAChR was the first ion channel protein to be isolated and purified, and
is classified as a transmitter, or ligand-gated channel.
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Nicotinic-AChR are clustered at the muscle endplate (each endplate has one to ten
million receptors), concentrated on the crests ofthepostjunctional membrane folds. Each
nAChR is a glycoprotein complex composed of five subunits, alpha, beta, epsilon, and
delta in a ratio of 2:1:1:1, with each of the two alpha subunits acting as an ACh binding
site [14, 17]. When simultaneously stimulated by two ACh molecules, the channel under-
goes conformational change and opens for about one millisecond, allowingrelatively non-
selective passage of small positively charged ions, mainly sodium (Na+, peak rate of
.30,000 ions per channel permillisecond), potassium, and some calcium. This Na+ influx
depolarizes the nearby muscle membrane, triggering local voltage-gated Na+-channels,
andthereby creates aself-propagating depolarization (i.e., an actionpotential). Excitation-
contraction coupling occurs, and muscle contraction results. Subsequently, the nAChR
channel recycles itselffor the next nerve impulse.
Normal neural activity and stimulation ofthe motorendplate regulates the translation
and membrane integration of the nAChR. Normal cholinergic neuron input is critical to
clustering nAChR underneath nerve terminals and maintaining a high concentration
(200,000 receptors/pm2) at the neuromuscular junction. Adult skeletal muscle retains an
ability to synthesize an immature nAChR variant, in which a gamma subunit is substitut-
ed for the normal epsilon subunit (Figure 1). In diseases such as Guillain-Barre, stroke,
polio, spinal cord injury, burns, severe muscle trauma, enforced immobilization, or other
conditions producing loss of nerve function, synthesis of immature (fetal) receptors may
be triggered. These immature nACh receptors are distinguished by three features. First,
immature receptors are not localized to the muscle endplate but migrate across the entire
membrane surface. Second, the immature receptors are metabolically short-lived (<24
hrs) and more ionically active, having a two- to 10-fold longer channel "open time."
Lastly, these immature receptors are more sensitive to the depolarizing effects of drugs
such as succinylcholine or decamethonium and more resistant to the effects ofcompeti-
tive antagonists such as d-tubocurarine. The clinical consequences of up-regulation of
these immature receptors are profound clinically [18]. In acute spinal cord injury and
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Figure 1.The mature, adult nicotinic acetylcholine receptor (left) and the immature, or fetal -
variant receptor (right). These receptors differ by a single subunit substitution, which produces
immature receptors characterized by ten-fold greater ionic activity, rapid metabolic turnover and
extrajunctional proliferation. (Reprinted with pernission from Martyn, J.A., White, D.A., Gronert,
G.A., et al. Anesthesiology 76:822, 1992.)
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burn patients, denervation-induced proliferation of immature gamma-subunit nACh
receptors likely explains the sensitivity and potentially-lethal hyperkalemic response to
depolarizing agonists like succinylcholine. In addition, this same phenomenon may
explain the drug resistance and tachyphylaxis to nondepolarizing NMB drugs.
TWITCH MONITORING IN THE ICU
Neuromuscular block in the operating room is routinely monitored by qualitative
grading of a motor response to transcutaneous peripheral nerve stimulation [19, 20]. In
this way, neuromuscular function can be assessed independently ofconfounding variables
such as sedation, depth of anesthesia or patient cooperation. Most authorities now univer-
sally recommend use of a hand-held peripheral nerve stimulator in the ICU to titrate the
depth of neuromuscular blockade and prevent significant and unnecessary NMB drug
overdose. Indeed, routine use of neuromuscular function monitoring with a peripheral
nerve stimulator has been advocated to limit, if not eliminate, prolonged weakness after
use of NMB drugs in the ICU [8]. While theoretically desirable, avoiding periods ofpro-
found (or complete) neuromuscular block with twitch monitoring in ICU patients cannot
guarantee return of normal neuromuscular function once the NMB drug is discontinued.
Traditionally, the ulnar nerve at the wrist is stimulated while evaluating the motor
response of the adductor pollicis brevis muscle of the thumb [19, 20]. Other peripheral
nerve sites (such as facial nerve stimulation while grading the orbicularis oculi muscle, or
stimulating the peroneal nerve ofthe upper leg and grading foot dorsiflexion) are also fea-
sible. Patients with strokes, paraplegia or dense peripheral neuropathies should be moni-
tored on unaffected limbs, since affected extremities will exhibit altered responses (resis-
tance) to neuromuscular blockade.
The train-of-four (TOF) response delivers four supramaximal stimuli (40 to 60 mA
current) at 2 Hz while the motor response of the 4th twitch (T4) is compared to the twitch
response of the first stimulus (TI) [19, 20]. Nondepolarizing block is characterized by a
progressive decrement in each successive motor twitch response, (a TOF response of
<0.7), the presence of fade during tetanic stimulation and the presence of post-tetanic
facilitation (Figure 2) [19, 20]. The main shortcoming of peripheral nerve stimulation is
that global muscle function is inferred from the response of a single peripheral muscle
group. For instance, the diaphragm and laryngeal muscles are more resistant to neuro-
muscular blockade than the adductor pollicis brevis muscle and also recover more quick-
ly after cessation of NMB drugs [21]. In some patients, a TOF count of 0 at the adductor
pollicis muscle may not correlate with a level of neuromuscular block sufficient to ade-
quately manage clinical endpoints such as elimination of coughing during suctioning,
eliminate peripheral motor movements, or dyssynchrony ("triggering") of the ventilator.
Thus, a TOF count of 0 does not necessarily represents a failure of monitoring or drug
titration but may reflect both the difficulty of administering NMB drugs in the ICU and
the need for clinical endpoints discrepant with the monitored twitch at the adductor polli-
cis. It is important, therefore, to utilize a combination ofboth peripheral nerve stimulation
and clinical assessment to evaluate neuromuscular function and degree of neuromuscular
blockade. Critically ill patients rarely require dense, 100 percent receptor blockade, espe-
cially when NMB drugs are accompanied by adequate delivery of sedative and analgesic
drugs. NMB drugs should be titrated to the minimally effective dose, maintaining the least
degree ofneuromuscular block that provides optimal patient care. Regardless, a fixed level
of neuromuscular block is difficult to maintain in ICU patients due to factors such as
changing body temperature, alterations of muscle blood flow, altered electrolytes, use of
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concomitant medications such as aminoglycosides, magnesium, calcium-channel block-
ers, and so forth.
NMB DRUGS AND COMPLICATIONS IN THE ICU
Use of NMB drugs in the ICU may be associated with numerous potential adverse
effects (Table 1). Precautions to limit these effects include a secured, unobstructed airway,
positive pressure ventilation, appropriate inspired oxygen concentration, concurrent seda-
tion and analgesia, precautions to avoid pressure on vulnerable points ofnerves, eyes, and
skin, and prophylaxis for deep venous thrombosis.
Nondepolarizing drug
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Figure 2.Top panel shows the effect of a nondepolarizing neuromuscular blocking (NMB) drug,
e.g., pancuronium, on the single twitch response at 1 Hz. The middle panel shows the effect of suc-
cinylcholine (a depolarizing NMB drug) on the train-of-four (TOF) response applied at 2 Hz after a
baseline period is established. Note that all four twitches are depressed equally, and that there is no
fade ofthe response during either onset orrecovery from this type ofneuromuscular block. The bot-
tom panel shows the more common effect of a nondepolarizing NMB drug producing a decrement
in the TOF response ("fade"). The TOF response can be advantagous in that no baseline period is
required for effective monitoring. In this case, recovery was hastened by use of the anti-
cholinesterase drug, neostigmine. (Reprinted with permission from Hunter, J.M. N. Engl. J. Med.
332:1691, 1995.)
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Table 1. Potential complications: NMB drugs in the ICU.
Complications and contraindications ofsuccinylcholine in the ICU:
* Immediate cessation of spontaneous respiration
* Hyperkalmia due to multiple risk factors [30]
* Increased intragastric pressure
* Increased intraocular pressure
* Parasympathomimetic effects with cardiac arrhythmias
* Muscle fasiculations (myoglobinemia, especially in children)
* Potential for Phase II block
General complications associated with NMB drugs in the ICU:
* Awake, paralyzed, stressed patient
* Risk ofventilator disconnect or airway mishap
* Autonomic and cardiovascular interactions
* Tachycardia or bradycardia; hypotension or hypertension
* Accumulation ofparent drug or drug metabolites
(e.g., Laudanosine, 3-desacetylvecuronium, 3-OH-pancuronium)
* Decreased lymphatic flow, impaired respiratory clearance
* Risk of generalized deconditioning, skin breakdown
* Peripheral nerve injury
* Comeal abrasion, conjunctivitis
* Risk ofprolonged muscle weakness and "postparalytic syndrome" (myopathy)
* Potential central nervous system toxicity
* Potential interactions with leukocytes
* Drug cost
Recent evidence documents unexpected complications after NMB use in the ICU,
including prolonged recovery and even myopathy during or after NMB drug administra-
tion [22-24]. These adverse events mayberelated to the frequent use ofNMB drugs, along
with the mode of administration, depth of neuromuscular blockade, the specific drug
administered, and NMB drug interactions. Unresolved issues include the postulated ben-
efit of routine twitch monitoring of neuromuscular function, definition of screening tests
for impending muscle injury, the allegedbenefit ofa"drug holiday" (whereby NMB drugs
are briefly discontinued once each day to examine neuromuscular recovery), the effects of
prolonged immobility, and the association ofneuromuscular pathology with sepsis. These
adverse effects may be divided into pharmacologic, physiologic, and toxic mechanisms
(the lateris the mostelusive to delineate). "Prolonged recovery" in the ICU will be defined
as neuromuscular recovery which requires significantly longer than expected (e.g., >120
min after discontinuation of intermediate-acting NMB drugs such as atracurium or
vecuronium) based on usual and recognized pharmacokinetic parameters for NMB drugs.
"Myopathy" will be defined as the clinical triad of persistent clinical paresis, increased
creatine phosphokinase (CK) concentrations and abnormal electromyography (EMG) and
nerve conduction studies after ICU administration ofNMB drugs.
Pharmacologic
The metabolism ofNMB ranges from negligible (and metocurine) to extensive (suc-
cinylcholine, vecuronium) [22-24]. Redistribution oflong-acting NMB drugs is important
in limiting the pharmacodynamic effects after a single bolus dose, as these drugs under-
go less biotransformation and more renal excretion ofunchanged drug. However, during
long-term ICU administration of NMB agents, drug excretion and production of active
drug metabolites are increasingly important. In the past, the steroid-based NMB drugs
(pancuronium and vecuronium) were most commonly used [25, 26], which may have
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contributed to the majority of case reports of prolonged weakness or myopathy being
associated with these particular NMB drugs [12]. This association of an increased risk
inferred by specific NMB drugs must also be critically examined in the dynamic milieu
ofheterogeneous ICU patients with altered drug pharmacokinetics. For instance, vecuro-
nium undergoes hepatic hydrolysis to three metabolites: 3-des, 17-des, and 3,17
desacetylvecuronium [11, 27]. These metabolites, excreted primarily in the bile, vary in
NMB activity. The 3-desacetyl metabolite is estimated to be 80 percent as potent as the
parent compound, while 17- and 3,17- metabolites are far less potent. The 3-desacetylve-
curonium metabolite accumulates in normal volunteers and patients in renal failure and
is poorly dialyzed and minimally ultrafiltrated. Vecuronium has a three-fold increase in
the elimination half-life due to an increased volume of distribution in patients receiving
prolonged administration. In addition, the hepatic elimination of 3-desacetylvecuronium
is decreased in patients uremic for >36 hours. The accumulation of both 3-desacetylve-
curonium and vecuronium inrenal failure likely contributes to prolonged weakness in this
subset of ICU patients. Similarly, pancuronium is a bisquatemary NMB drug, which is
desacetylated at the C3- position of the steroid nucleus to 3 desacetylpancuronium. The
3-OH metabolite is lipophilic, 90 percent bound to plasma proteins, approximately 50
percent as active as the parent pancuronium, and may accumulate in patients with renal
insufficiency. The combination ofdecreased clearance, increased volume ofdistribution,
and accumulation of active 3-OH-metabolites in renal failure may be a pharmacologic
mechanism for prolonged weakness in some ICU patients.
Table 2. Drug-drug interactions: neuromuscular blocking (NMB) drugs.
Drugs that potentiate the action ofnondepolarizing NMB drugs:
* Local anesthetics
* Lidocaine
* Antibiotics
* Aminoglycosides (gentamicin, tobramycin, amikacin)
* Polypeptides (polymyxin B)
* Other antibiotics (clindamycin, tetrcyclin)
* Antiarrhythmics
* Procainamide
* Quinidine
* Magnesium
* Calcium-channel blockers
* fB-adrenergic blockers
* Chemotherapeutic agents
* Cyclophosphamide
* Dantrolene
* Diuretics
* Furosemide (biphasic response)
* Thiazides
* Lithium carbonate
* Cyclosporine
Drugs that antagonize the actions ofnondepolaring NMB drugs:
* Penytoin
* Carbamazepine
* Theophylline
* Ranitidine
* Chronic exposure to nondepolarizing NMB drugs
474Prielipp: Neuromuscular blocking drugs in the ICU
There are a wide range of drugs with complex interactions with NMB drugs. These
drug-drug interactions may either antagonize or potentiate the effect of NMB drug motor
block (Table 2). Attention is focused on patients who receive both NMB drugs and exoge-
nous corticosteroids [12, 28]. The long-term effect and potential toxicity of some ofthese
interactions has yet to be defined, especially those not secondary to altered pharmacoki-
netics or dynamics.
What can be done to decrease the incidence ofprolonged weakness in the ICU after
NMB administration? Transcutaneous peripheral nerve stimulation may facilitate neuro-
muscular assessment independent of confounding ICU variables such as sedation, alter-
ations in mental status or patient cooperation, and thereby facilitate more precise titration
of NMB drug therapy. Indeed, routine use of neuromuscular function monitoring with a
peripheral nerve stimulator has been advocated to limit, ifnot eliminate, prolonged weak-
ness after use ofNMB drugs in the ICU. Unfortunately, recent evidence does not support
this hypothesis. While theoretically desirable, avoiding periods ofprofound (or complete)
neuromuscular block with twitch monitoring in ICU patients cannot guarantee return of
normal neuromuscular function once the NMB drug is discontinued. Prielipp reported the
use ofeither vecuronium or cisatracurium (51W89) for an average ofthree days in 58 ICU
patients. Despite the routine use ofneuromuscular twitch monitoring, 15 patients demon-
strated prolonged recovery, and one patient developed a profound myopathy (139 days)
[29]. The reason may be certain limitations noted with peripheral nerve monitoring in the
ICU. For instance, a train-of-four (TOF) count of 1 or 2 at the adductor pollicis muscle
may not correlate with a level of neuromuscular block sufficient to adequately manage
clinical endpoints such as elimination of coughing during suctioning, eliminate peripher-
al motor movements or asynchrony ("triggering") of the ventilator. For instance, in
patients with critically elevated intracranial pressure, an exceptionally deep level of neu-
romuscular block is required to ablate the tracheal reflex to endotracheal suctioning. Thus,
in certain situations in the ICU, a TOF count of 0 (at the adductor pollicis) is required,
markedly decreasing the functional utility oftwitch monitoring as a safeguard from exces-
sive NMB doses.
Physiologic
Pathophysiologic changes occur at the nerve, neuromuscular junction and muscle in
critically ill patients. Physiologic changes are enhanced when patients are immobilized or
denervated secondary to CNS or spinal cord injury as well as during NMB drug-induced
paralysis. The nAChR may be triggered to revert to a fetal variant structure, characterized
by an increase in total number, frequent extrajunctional proliferation and "resistance" to
nondepolarizing NMB drugs. This may account forthe observations ofsome ICU patients
developing tachyphylaxis to NMB drugs. The proliferation and distribution of these
altered receptors across the myomembrane may, however, simultaneously sensitize
patients to depolarizing drugs such as succinylcholine. Succinylcholine stimulation ofthe
immature, fetal receptors allows increased cation transport, which may clinically manifest
as life-threatening hyperkalemia in these patients [30].
Additional investigation and evaluation on the effect ofprolonged NMB exposure to
nerves, neuromuscular junctions and muscle are still ongoing. For instance, there is
increasing recognition of an entity termed critical illness polyneuropathy (CIP). The sen-
sory and motor polyneuropathy of CIP differentiates this process from other neurologic
and myopathic processes encountered in the critically ill (Table 3). CIP occurs most com-
monly in elderly, septic patients who are severely ill for prolonged periods [31-33]. Up to
70 percent of septic ICU patients are reported to develop some elements of CIP. The
process is associated with a high mortality, but ifpatients survive their underlying disease,
they may make a full recovery. However, recovery requires a protracted period (three to
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Table 3. Possible causes ofweakness in ICU patients.
* Residual NMB drug effect
Secondary to parent drug, drug metabolite or drug-drug interaction
* Myasthenia gravis
* Eaton-Lambert syndrome
* Muscular dystrophies
* Guillian-Barre
* Central nervous system injury or lesion
* Spinal cord injury
* Steroid myopathy
* Critical illness polyneuropathy
* Disuse atrophy
* Severe electrolyte toxicity (e.g., magnesium)
* Severe electrolyte deficiency (e.g., hypophosphatemia)
six months) of hospitalization and supportive care. CIP is a diagnosis of exclusion, after
examination of the clinical setting, determination of a diffuse sensorimotor deficit, and
EMG and nerve conduction studies. CIP is hypothesized to be a result ofprimary axonal
degeneration, perhaps related to microvascular ischemia ofthe nerve during SIRS. It does
not appear to be directly related to the use ofNMB drugs. It is further differentiated from
Guillain Barre by the absence of inflammatory changes in nerve fibers and the presence
ofnormal cerebrospinal fluid.
Toxic
The incidence ofprolonged weakness after NMB drugs remains unknown, although
Op de Coul and colleagues reported prolonged weakness (of unknown and variable) eti-
ology in 20 percent ofconsecutive patients who received long-term administration ofpan-
curonium [10]. Murray et al. prospectively monitored patients in the ICU at the Mayo
Clinic and estimated the risk ofclinically significant prolonged neuromuscular block was
five percent [1]. The actual incidence is likely dependent on numerous factors, perhaps
including the administration of various antibiotics (aminoglycosides), corticosteroids,
anticonvulsants, magnesium, calcium-channel blocking drugs and other medications that
may interact with NMB drugs. The incidence of true myopathy is certainly less than the
occurrence ofprolonged weakness in the ICU.
The direct toxicity ofNMB drugs is poorly characterized and may be additive to alter-
ations ofNMB drug pharmacology discussed previously. In addition, alterations in nerve,
muscle and neurotransmission may increase the toxicity of normally non-toxic drugs or
drug metabolites. Concerns about untoward effects of NMB drugs in the ICU have lead
some to even advocate elimination of prolonged use of NMB drugs in critically ill
patients. Others have suggested that certain NMB drugs may be better suited than others
in the ICU setting with renal failure, hepatic failure, NMB drug tachyphylaxis, or concur-
rent use of parenteral corticosteroids (e.g., for status asthmaticus, ARDS, connective tis-
sue disease, etc). Unfortunately, much ofthe evidence remains anecdotal.
The acute myopathy, oftenreferred to as "post-paralytic quadriparesis ortetraparesis"
is an infrequent, but major complication after prolonged NMB administration in the crit-
ically ill. This entity must be differentiated from other neuromuscular pathologies noted
above (Table 3).Afflicted patients demonstrate diffuse weakness, whichpersists long after
the NMB drug administration is discontinued. Neurologic examination reveals primarily
a global motor deficit and tends to afflict proximal and distal muscles equally. Barohn et
al. described three patients with myopathy, characterized by low amplitude compound
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motor action potentials, normal sensory studies and fibrillations [34]. Muscle biopsy
showed loss of thick, myosin filaments. Variable increases in CK may be detected,
depending on the timing oflab determinations and the initiation ofthe myopathic process.
Thus, there may be some justification in routinely screening high risk patients with serial
CK determinations during the infusion ofNMB drugs. It is unclear whether drug combi-
nations such as aminosteroid NMB drugs and concurrent administration of exogenous
corticosteroids infer any specific increased risk, but is probably best avoided.
There are now a small number ofreports ofa myopathy developing after ICU admin-
istration of the benzylisoquinolinium NMB drugs (e.g., atracurium) [35]. We and others
have diagnosed myopathy (clinical weakness, increased CK concentrations, and abnormal
EMG studies) in patients after atracurium was administered for 3-4 days in the ICU.
However, these patients also received corticosteroids, aminoglycosides, and one suffered
chronic renal insufficiency. Myopathy occurred in both of our ICU patients despite the
routine use of a peripheral nerve twitch monitor to titrate NMB drug administration.
The diagnosis of the patient with prolonged weakness, paresis, and possible myopa-
thy after discontinuation of NMB drugs requires a systematic approach. This includes a
thorough history and physical examination combined with review of recent medications
and identification of related nerve or muscle pathology. First, potential residual neuro-
muscular blockade should be investigated with a peripheral nerve stimulator. In addition,
early neurologic consultation with appropriate diagnostic examination including
EMG/NCV, CK analysis, and muscle biopsy should be undertaken when indicated.
PROSPECTIVE STUDIES OF NMB DRUGS IN THE ICU
Rocuronium
Sparr reported rocuronium drug requirements for bolus administration (median dose
= 0.34 mg/kg/hr) and continuous infusion (0.54 mg/kg/hr) in 32 adult ICU patients [36].
NMB drug requirements decreased during the first six to nine hours, because the T1/26
(terminal half-life) and the volume ofdistribution at steady state increased three-fold [36].
Circeo confirmed these findings in ten adult ICU patients where the mean rocuronium
infusion rate during the first four hours (8.1 pg/kg/min) decreased significantly after 24
hours (5.2 pg/kg/min) [37]. Median time for recovery to the fourth twitch in the TOF stim-
ulation was 60 to 100 min, but recovery to the more robust 70 percent T4/T1 ratio was
widely variable (99-1157 min) [37].
Doxacurium andpancuronium
Murray compared bolus injection of pancuronium (0.05 mg/kg) and doxacurium
(0.025 mg/kg) in a double-blind, randomized study of 40 severely ill, adult patients para-
lyzed for two to three days in the ICU, using twitch monitoring to guide intermittent NMB
drug administration [38]. Pancuronium significantly increased heart rate 11 beats per
minute, whereas there was no change after doxacurium. Furthermore, neuromuscular
recovery (to appearance ofT4 in the TOF stimulus) was more variable and prolonged (279
± 229 min) after pancuronium, compared to recovery following doxacurium (138 ± 46
min) [38]. Patients who received pancuronium with concomitant renal insufficiency (cre-
atinine clearance <50 mL/min) were most likely to exhibit prolonged recovery.
The dose requirements and neuromuscular recovery of doxacurium administered as a
continuous infusion has recently been defined in adult ICU patients with head injuries
[39]. Patients were paralyzed for 66 ± 12 hours (range 20 to 109.5 hours). The doxacuri-
um infusion rate appeared similar at the beginning (1.0 ± 0.1 mg/hr) and end of the study
(1.3 ± 0.4 mg/hr). Doxacurium bolus had no effect on heart rate, mean arterial pressure or
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intracranial pressure. Afterdiscontinuation ofdoxacurium infusion, neuromuscularrecov-
ery required 118 ± 19 min (note similarity to the recovery times reported by Murray et
al.). There were no complications, prolonged weakness or myopathies in this select group
ofpatients with traumatic brain injury.
Cisatracurium and vecuronium
Thedose-response andrecoverypharmacodynamics oftwo intermediate-acting NMB
drugs, cisatracurium and vecuronium, were compared in a prospective, randomized, dou-
ble-blind, multicenter study in 58 critically ill adults [29]. These NMB drugs were admin-
istered as an infusion for one to five days, titrated by peripheral nerve stimulation and
twitch monitoring. Cisatracurium infusion averaged 2.6 ± 0.2 pg/kg'1/min-I for a mean
duration of 80 ± 7 hours. Neuromuscular recovery to 70 percent TOF ratio was 63 ± 12
min. Vecuronium infusion averaged 0.9 ± 0.1 pg/kg1/min-1 for a mean duration of 66 +
12 hours. The mean time to neuromuscular recovery after vecuronium was significantly
longer (387 ± 163 minutes). In addition, prolonged recovery of neuromuscular function
occurred more commonly after vecuronium drug infusion (13 of 30 patients), compared
to cisatracurium (two of 28 patients).
Cisatracurium and atracurium
The pharmacodynamics andpharmacokinetics ofthe two benzylisoquinolinium inter-
mediate-acting NMB drugs, cisatracurium and atracurium, were examined in a prospec-
tive, randomized, double-blind, study in 12 mechanically ventilated ICU patients para-
lyzed for 1-2 days [40]. Neuromuscular recovery to 70 percent TOF ratio required 60 min
after the cisatracurium infusion and 62 min following atracurium. Cisatracurium was 2.5
times more potent than atracurium in these ICU patients, which translated into signifi-
cantly lower plasma laudanosine concentrations after cisatracurium (peak value = 1.3
pg/mL) compared to atracurium (maximum concentration = 4.4 pg/mL) [40].
Other controversies associated with NMB drugs in the ICU
NMB Drugs and Patients with Head Trauma. At least 50 percent of patients with
severe head injury and brain trauma will manifest intracranial pressure (ICP) >20 mm Hg.
While the pathologic consequences of increased ICP are still being defined, patient out-
come afterheadinjury is worse when ICPremains elevated. Managementtraditionally uti-
lized controlled hyperventilation, fluid restriction, head elevation, diuretics, cerebrospinal
fluid drainage, and it was commonpractice in many neurosurgical ICUs for patients to be
managed by a protocol that included routine use of NMB drugs. Paralysis with NMB
drugs can effectively prevent orblunt the potent sympathetic and otherreflex responses to
tracheal suctioning, which will otherwise result inrapid increases in ICP [41]. In addition,
ofcourse, NMB drugs facilitate controlled hyperventilation. Despite the efficacy ofNMB
drugs in facilitating control of intracranial hypertension in patients with head injury,
administration of NMB drugs (as part of a routine protocol in trauma ICU patients) has
not been documented to improvepatient outcome [42]. Hsiang et al. reviewed 514patients
with severe head trauma (Glasgow Coma Scale <8) collated in the Traumatic Coma Data
Bank from 1984 to 1987 [43]. Approximately half these patients received early, and rou-
tine, use of NMB drugs, while the other half did not meet these criteria. Patients receiv-
ing early, routine use ofNMB drugs (Group 1) were characterized by significantly longer
ICU stay (8 vs. 5 days), more frequent pneumonia, and a trend towards a higher rate of
sepsis [43]. While the mortality was lower in Group 1 patients receiving early NMB drugs
(24 percent vs. 39 percent, p < .001), this group also had significantly more vegetative and
severely disabled survivors. Significant limitations are inherent in this study, but it raises
pertinentquestions, and aprospective study is warranted. Currently, the use ofNMB drugs
478Prielipp: Neuromuscular blocking drugs in the ICU
to help control ICP in patients with head trauma remains controversial, as therapeutic pri-
orities in the management of acute head injury continue to evolve.
INDICATIONS AND DRUG SELECTION
Evidence-based information is limited to guide appropriate NMB drug administration
in the ICU. A task force of clinicians and other experts from the American College of
Critical Care Medicine and the Society ofCritical Care Medicine published guidelines in
1995 for use of NMB drugs in the ICU [44]. However, none of the three published rec-
ommendations were supported by Level 1 evidence, which was defined as that which
would be "convincingly justifiable on scientific evidence alone." In addition, their infor-
mation and Medline database was limited to that available by 1995, and several new, ran-
domized studies have appeared in the literature since that time (see section on
"Prospective Studies of NMB Drugs in the ICU," above). Thus, the opinions expressed
below may differ significantly from those ofearlier guidelines.
Pharmacodynamic characteristics of current NMB drugs are summarized in Table 4,
and are considered in extensive detail elsewhere [13, 45-49]. It is always appropriate, and
often sufficient, to maximize sedation and analgesia before consideration ofNMB drugs.
Many ICU patients may be adequately managed and ventilated with appropriate use of
benzodiazepines, propofol and narcotics. When necessary, it is common practice to initi-
ate neuromuscular block with a bolus-loading dose and subsequent infusion ofone ofthe
intermediate-duration (cisatracurium, rocuronium) [29, 36, 37] or long-duration (dox-
acurium, pipecuronium) NMB drugs [38, 39, 50]. These drugs are noteworthy for hemo-
dynamic stability and a duration of action of 0.5-1.5 hours. In renal failure patients or
those with multiorgan dysfunction syndrome, cisatracurium exhibits advantages of
Hofmann elimination and the lack of active NMB metabolites [40]. Laudanosine produc-
tion secondary to cisatracurium metabolism is only 20-30 percent of that previously
observed with use of atracurium. If a NMB drug with a longer duration of action is
desired, doxacurium has proven safe [38, 39]. In addition, because of its long half-life, it
may be administered by intermittent bolus or continuous infusion with equal efficacy [38,
39]. In the ICU, drug-drug interactions are common and must also be considered (Table
2). For instance, caution should be exercised in ICU patients receiving therapeutic corti-
costeroids and concurrent administration ofsteroid-based NMB drugs. Evidence suggests
at least an association between vecuronium or pancuronium, use of exogenous corticos-
teroids, and subsequent development of prolonged muscle weakness (including "tetra-
paresis" or"quadraparesis") [5, 10, 34, 51]. In general, the recovery profiles ofthe steroid-
based NMB drugs (rocuronium, vecuronium, pipecuronium, pancuronium) tend to be
longer and more variable compared to their benzylisoquinolinium-based counterparts
(cisatracurium, atracurium, doxacurium, metocurine) [28, 39]. In any case, it may be pru-
dent to monitor daily CK enzyme levels in patients receiving high-dose steroids and any
NMB drug.
The pharmacologic development of tachyphylaxis may be seen in adult or pediatric
ICU patients receiving prolonged neuromuscular block, usually within 24 to72 hrs of
onset of neuromuscular blockade [52, 53]. Based on speculation and anecdotal evidence,
tachyphylaxis may occur more commonly in patients receiving NMB drugs as a continu-
ous infusion, as opposed to intermittent bolus administration. Multiple factors account for
tachyphylaxis to NMB drugs in ICU patients, including the proliferation ofextrajunction-
al nACh receptors and an increase in the number of neuromuscular receptor sites [54].
Chronic, partial neuromuscular blockade, similar to partial or complete deafferentation
injury, may trigger proliferation of (fetal variant) nACh receptors [18].
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Lastly, NMB drugs may constitute a significant fraction ofthe hospital pharmaceuti-
cal budget [15, 16, 55]. The costs associated with NMB drug utilization and prolonged
weakness after NMB drugs are increasingly a consideration in drug selection. Costs vary
between drugs, and are affected by the mode of administration, bedside monitoring of
neuromuscular function and the amount ofnursing time required. In addition, occasional
patients with unexpected, prolonged muscle weakness will require extended ICU and hos-
pital care, significantly increasing costs. In general, newer drugs (Table 4) are more cost-
ly. Older NMB drugs are less expensive, but have less precedent to support their extend-
ed use in the ICU. Prolonged weakness or myopathy in the ICU environment may result
in many weeks (or even months) of additional ICU care and hospital rehabilitation. A
recent economic analysis attempted to quantitate the hospital charges associated with 10
such unfortunate patients. The median additional charges associated with patients who
developed prolonged neuromuscular weakness was >$66,000 perpatient (excluding reha-
bilitation), but could reach $200,000 in selected cases [16]. Significant costs were attrib-
uted to the requirement for additional mechanical ventilation, neurologic studies, ICU
care and hospital days.
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